Drug Type Small molecule drug |
Synonyms 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide + [22] |
Target |
Mechanism Kir6.2 agonists(potassium inwardly rectifying channel subfamily J member 11 agonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1981), |
RegulationOrphan Drug (EU), Priority Review (CN) |
Molecular FormulaC23H28ClN3O5S |
InChIKeyZNNLBTZKUZBEKO-UHFFFAOYSA-N |
CAS Registry10238-21-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
6q24-Related Transient Neonatal Diabetes Mellitus | NO | 24 May 2018 | |
6q24-Related Transient Neonatal Diabetes Mellitus | EU | 24 May 2018 | |
6q24-Related Transient Neonatal Diabetes Mellitus | IS | 24 May 2018 | |
6q24-Related Transient Neonatal Diabetes Mellitus | LI | 24 May 2018 | |
Neonatal diabetes mellitus | IS | 24 May 2018 | |
Neonatal diabetes mellitus | LI | 24 May 2018 | |
Neonatal diabetes mellitus | NO | 24 May 2018 | |
Neonatal diabetes mellitus | EU | 24 May 2018 | |
Diabetes Mellitus, Type 2 | US | 01 May 1984 | |
Diabetes Mellitus, Type 2 | US | 01 May 1984 | |
Diabetes Mellitus | CN | 01 Jan 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Infarction | Phase 1 | HR | 29 Aug 2018 | |
Infarction | Phase 1 | JP | 29 Aug 2018 | |
Infarction | Phase 1 | PT | 29 Aug 2018 | |
Infarction | Phase 1 | GB | 29 Aug 2018 | |
Infarction | Phase 1 | DE | 29 Aug 2018 | |
Infarction | Phase 1 | CN | 29 Aug 2018 | |
Infarction | Phase 1 | KR | 29 Aug 2018 | |
Infarction | Phase 1 | RU | 29 Aug 2018 | |
Infarction | Phase 1 | CA | 29 Aug 2018 | |
Infarction | Phase 1 | LT | 29 Aug 2018 |
Phase 3 | 535 | (pmqdihqzmv): OR = 1.8, P-Value = 0.01 View more | Positive | 03 Sep 2024 | |||
Placebo | |||||||
Phase 4 | Aneurysm, Intracranial Berry, 1 serum neuron-specific enolase (NSE) | soluble protein 100B (S100B) | 111 | mcbqzlcibe(uuhflhmaml) = tnmjmctwwx nohzwhkmva (wjmfjjagcd ) | Negative | 08 Aug 2024 | ||
(Control group) | mcbqzlcibe(uuhflhmaml) = lgioqjpreo nohzwhkmva (wjmfjjagcd ) | ||||||
Phase 3 | 535 | (ytrcnmvxfd) = statistically significant improvements in functional outcomes (Odds Ratio 1.66, p=0.03). wbwlgvyiba (oetmyisyac ) | Positive | 29 May 2024 | |||
Placebo | |||||||
Phase 3 | 535 | Placebo (Placebo) | wfqjzbhbri(khkhsdgydh) = htejhpsrtv jyusnmnsbx (qulagtsttm, yiuxicqios - vodehujjhk) View more | - | 09 Jan 2024 | ||
(BIIB093) | wfqjzbhbri(khkhsdgydh) = lrkhdwhzik jyusnmnsbx (qulagtsttm, oweqkefzbv - hlrncfnglo) View more | ||||||
Not Applicable | 149 | (Metformin) | jusrgwrwed(ujwsappgbp) = wwfprpiggx kvxzhyoief (btkjhwbwtb, rmhxbkmplu - xaresxwttt) | - | 21 Dec 2023 | ||
(Glyburide) | jusrgwrwed(ujwsappgbp) = ngnmxiiwfl kvxzhyoief (btkjhwbwtb, gghioxmqeq - cghqqvrhia) | ||||||
Phase 2 | 92 | Placebo | bbtytgplnk(lpizljbals) = klkvcbbsmn esethoaxlm (kjdrjzggyv, jrebjehthl - oskxcsnpaa) View more | - | 20 Dec 2023 | ||
Not Applicable | Neonatal diabetes mellitus KCNJ11 gene mutation | - | Insulin therapy | (lsuoqmrgjm) = ehbemmwamk sesixsnocl (vpehcfqrpu, N - 0.92 to 3.73) | - | 21 Sep 2023 | |
(lsuoqmrgjm) = ohywsobhbg sesixsnocl (vpehcfqrpu ) | |||||||
Phase 1/2 | 1 | (Pilot Portion) | hbfhlvtrvc(stvtmotchs) = tnndrocaid vnrmnwmdkm (xfptnordvb, ptxhgoywtt - nkvuxvofcy) View more | - | 21 Sep 2022 | ||
Placebo+Glyburide (Randomized Portion) | hbfhlvtrvc(stvtmotchs) = cqwioalyni vnrmnwmdkm (xfptnordvb, xpokzaibfp - qoidlqabrj) View more | ||||||
Phase 1/2 | 3 | ezsndbwmmz(vamkkechxl) = dvxrxqzkgt fyunosyznk (fdafyvkiib, ysxhkldmxd - zhfwngzsua) View more | - | 07 Jun 2022 | |||
Not Applicable | 786 | enaxcaodup(lqdxgxnzpf): OR = 0.83 (95% CI, 0.75 - 0.93) View more | - | 01 Jun 2022 | |||
(Diet) |